Thanks to the yahoo thread for pointing to
this pdf today, I had not thought to listen
to the archived call or anything (not that
interested in Galapagos)
But page 13 is sorta interesting: Biofocus
puts themselves along side Array, Albany,
Evotec and Lexicon.
(for you listkeepers out there. I never
think of Lexicon in that camp, but I will now)
glpg.com
crucell.com
From the start, Galapagos has operated a hybrid business model, combining internal discovery programs with service activities. The joint venture operated until 2002 when the Company raised €23.4 million in a private placement. In May 2005, the Company raised €22.4 million through its initial public offering on the Euronext Brussels and Euronext Amsterdam stock exchanges. In October 2005, Galapagos acquired BioFocus, a drug discovery company based in Saffron Walden, UK, through an all share offer, giving BioFocus shareholders a 29% state holding in the enlarged Company. On October 20, 2005 Galapagos started trading on the Alternative Investment Market of the London Stock Exchange. |
